Connor, Clark & Lunn Investment Management Ltd. Denali Therapeutics Inc. Transaction History

Connor, Clark & Lunn Investment Management Ltd.

$18.8 Billion
Q3 2024

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2022 Feb 10, 2023	SELL	$26.28 - $33.92 $1.35 Million - $1.74 Million	-51,436 Reduced 45.71%	61,096 $1.7 Million
Q3 2022 Nov 10, 2022	BUY	$25.97 - $38.53 $2.92 Million - $4.34 Million	112,532 New	112,532 $3.45 Million
Q3 2021 Nov 12, 2021	SELL	$48.48 - $78.23 $969,260 - $1.56 Million	-19,993 Closed	0 $0
Q2 2021 Aug 12, 2021	SELL	$50.3 - $78.44 $901,023 - $1.41 Million	-17,913 Reduced 47.26%	19,993 $1.57 Million
Q1 2021 May 13, 2021	BUY	$53.8 - $81.53 $980,720 - $1.49 Million	18,229 Added 92.64%	37,906 $2.16 Million
Q4 2020 Feb 16, 2021	BUY	$36.89 - $93.56 $725,884 - $1.84 Million	19,677 New	19,677 $1.65 Million

Others Institutions Holding DNLI

# of Institutions

234

Shares Held

119M

Call Options Held

60.6K

Put Options Held

48.4K

Black Rock Inc. New York, NY

13.2M
Shares

$293 Million
0.01% of portfolio
Baillie Gifford & CO

12.3M
Shares

$274 Million
0.2% of portfolio
Vanguard Group Inc Valley Forge, PA

11.2M
Shares

$249 Million
0.01% of portfolio
Wellington Management Group LLP Boston, MA

10.7M
Shares

$239 Million
0.06% of portfolio
Capital Research Global Investors Los Angeles, CA

7.91M
Shares

$176 Million
0.05% of portfolio

View Full List

About Denali Therapeutics Inc.

Ticker DNLI
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 134,174,000
Market Cap $2.99B
Description
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatm...

More about DNLI

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Connor, Clark & Lunn Investment Management Ltd., based on Form 13F filings with the SEC.

News

Stay updated on Connor, Clark & Lunn Investment Management Ltd. with notifications on news.

Account